Advanced oxidation protein products as a biomarker of cutaneous lupus erythematosus complicated by nephritis: A case-control study

Genetics and Molecular Research

Volumn 13, Issue 4, 2014, Pages 9213-9219

  Xie, Z ^a   Zhang, M ^b   Zhao, B ^a   Wang, Q ^a   Li, J ^a   Liu, Y Y ^a   Chen, Y H ^c  

^a SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Advanced oxidation protein products; Biomarker; Case control study; Cutaneous lupus erythematosus; Lupus nephritis; Prognosis

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SKIN LUPUS ERYTHEMATOSUS; COMPLICATION; METABOLISM; OXIDATION REDUCTION REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; OXIDATION-REDUCTION;

EID: 84909947437     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2014.November.7.8     Document Type: Article

References (20)

1. Ames PR, Alves J, Pap AF, Ramos P, et al. (2000). Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J. Rheumatol. 27: 1190-1195.
2. Bombardier C, Gladman DD, Urowitz MB, Caron D, et al. (1992). Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35: 630-640.
3. Capeillere-Blandin C, Gausson V, Nguyen AT, Descamps-Latscha B, et al. (2006). Respective role of uraemic toxins and myeloperoxidase in the uraemic state. Nephrol. Dial. Transplant. 21: 1555-1563.
4. Chen YH, Shi W, Liang XL, Liang YZ, et al. (2011). Effect of blood sample type on the measurement of advanced oxidation protein products as a biomarker of inflammation and oxidative stress in hemodialysis patients. Biomarkers 16: 129-135.
5. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, et al. (2004). Early prediction of IgA nephropathy progression: proteinuria and AOPP are strong prognostic markers. Kidney Int. 66: 1606-1612.
6. Fismen S, Petter Rekvig O and Synnøve Mortensen E (2007). Pathogenesis of SLE Dermatitis - A Reflection of the Process in SLE Nephritis? Curr. Rheumatol. Rev. 3: 165.
7. Hanasand M, Omdal R, Norheim KB, Goransson LG, et al. (2012). Improved detection of advanced oxidation protein products in plasma. Clin. Chim. Acta 413: 901-906.
8. Kalousova M, Skrha J and Zima T (2002). Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 51: 597-604.
9. Knight JS and Kaplan MJ (2012). Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr. Opin. Rheumatol. 24: 441-450.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, et al. (2009). A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150: 604-612.
11. Li HY, Hou FF, Zhang X, Chen PY, et al. (2007). Advanced oxidation protein products accelerate renal fibrosis in a remnant kidney model. J. Am. Soc. Nephrol. 18: 528-538.
12. Lozovoy MA, Simao AN, Panis C, Rotter MA, et al. (2011). Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. Lupus 20: 1250-1259.
13. Mok CC (2011). Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese. Lupus 20: 767-771.
14. Petri M and Magder L (2004). Classification criteria for systemic lupus erythematosus: a review. Lupus 13: 829-837.
15. Sergent JS, Sherman RL and Al-Mondhiry H (1976). Fibrinogen catabolism in systemic lupus erythematosus. Arthritis Rheum. 19: 195-198.
16. Servettaz A, Guilpain P, Goulvestre C, Chereau C, et al. (2007). Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann. Rheum. Dis. 66: 1202-1209.
17. Vera-Recabarren MA, Garcia-Carrasco M, Ramos-Casals M and Herrero C (2010). Comparative analysis of subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus: clinical and immunological study of 270 patients. Br. J. Dermatol. 162: 91-101.
18. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, et al. (1996). Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 49: 1304-1313.
19. Witko-Sarsat V, Friedlander M, Nguyen KT, Capeillere-Blandin C, et al. (1998). Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161: 2524-2532.
20. Yazici C, Kose K, Calis M, DemIr M, et al. (2004). Increased advanced oxidation protein products in Behcet’s disease: a new activity marker? Br. J. Dermatol. 151: 105-111.